Drug Type Antisense oligonucleotides |
Synonyms CDR, CDR 132L, CDR132L |
Target |
Mechanism miR-132 inhibitors(microRNA 132 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date16 Aug 2022 |
Sponsor / Collaborator |
Start Date27 Jun 2022 |
Sponsor / Collaborator |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Cardiomegaly | Phase 2 | - | Cardior Pharmaceuticals GmbHStartup | 01 Apr 2024 |
Heart failure with normal ejection fraction | Phase 2 | - | Cardior Pharmaceuticals GmbHStartup | 01 Apr 2024 |
Heart failure with reduced ejection fraction | Phase 2 | - | Cardior Pharmaceuticals GmbHStartup | 01 Apr 2024 |
Acute myocardial infarction | Phase 2 | CZ | Cardior Pharmaceuticals GmbHStartup | 27 Jun 2022 |
Acute myocardial infarction | Phase 2 | DE | Cardior Pharmaceuticals GmbHStartup | 27 Jun 2022 |
Acute myocardial infarction | Phase 2 | GR | Cardior Pharmaceuticals GmbHStartup | 27 Jun 2022 |
Acute myocardial infarction | Phase 2 | HU | Cardior Pharmaceuticals GmbHStartup | 27 Jun 2022 |
Acute myocardial infarction | Phase 2 | NL | Cardior Pharmaceuticals GmbHStartup | 27 Jun 2022 |
Acute myocardial infarction | Phase 2 | PL | Cardior Pharmaceuticals GmbHStartup | 27 Jun 2022 |
Acute myocardial infarction | Phase 2 | ES | Cardior Pharmaceuticals GmbHStartup | 27 Jun 2022 |
Study | Phase | Population | Analyzed Enrollment | Group | Results | Evaluation | Publication Date |
---|
Phase 1 | 28 | rqlbepnrib(xfuvctvskp) = btxphfpxin gagmasfxed (vhzyvdopdq ) | Positive | 07 Jan 2021 | |||
Placebo | rqlbepnrib(xfuvctvskp) = innttzpxmk gagmasfxed (vhzyvdopdq ) |